Candida auris: проблемы диагностики и лечения
https://doi.org/10.15690/vsp.v19i1.2081
Аннотация
Грибковые инфекции в последнее время представляют все большую опасность для длительно пребывающих в стационаре пациентов, которые получают иммуносупрессивную терапию и страдают иммунодефицитными состояниями. Обзор литературы посвящен Candida auris, впервые выделенной в 2009 г. В дальнейшем стало известно, что этот грибок является причиной нозокомиальных инфекций, летальность при которых достигает 72%. C. auris обладает множественной лекарственной устойчивостью, способна длительно существовать в окружающей среде. Основную проблему в клинической практике представляет недостаточная чувствительность существующих диагностических тестов для обнаружения этого грибка, что приводит к неверному подбору терапии и увеличивает риск фатального исхода инфекции. В последнем отчете Центра по контролю заболеваний (США) C. auris выделена в группу инфекционных агентов, представляющих наибольшую опасность для общественного здравоохранения.
Ключевые слова
Candida auris,
грибковая инфекция,
лекарственная устойчивость,
мультирезистентность,
мультирезистентный микроорганизм,
противогрибковые препараты,
профилактика инфекций,
эпидемиология
При поддержке: Не указан.
Об авторах
А. А. Иванов
Морозовская городская детская клиническая больница
Россия
Раскрытие интересов:
Россия
Иванов Артем Александрович - клинический ординатор Морозовской ДГКБ, врач-педиатр.
119049, Москва, 4-й Добрынинский пер., д. 1/9, корп. 22А.
Тел.: +7 (495) 959-88-01
Раскрытие интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить.
Т. В. Куличенко
Морозовская городская детская клиническая больница; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Россия
Москва.
Раскрытие интересов:
Россия
Москва.
Раскрытие интересов:
Авторы статьи подтвердили отсутствие конфликта интересов, о котором необходимо сообщить.
Список литературы
1. Global Action Fund for Fungal Infections [Internet], Global Action Fund for Fungal Infection. Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade [cited 2017 April 5]. Available from: http://gaffi.org/wp-content/uploads/GAFFI_Road_Map_interactive-final0415.pdf.
2. Tudela JL, Denning DW. Recovery from serious fungal infections should be realisable for everyone. Lancet Infect Dis. 2017;17(11):1111-1113. doi:10.1016/S1473-3099(17)30319-5.
3. Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(156):165rv13. doi:10.1126/scitranslmed.3004404.
4. Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26.
5. Pfaller MA. Epidemiology of nosocomial candidiasis: the importance of molecular typing. Braz J Infect Dis. 2000;4:161-167.
6. Satoh K, Makimura K, Hasumi Y et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-44. doi:10.1111/j.1348-0421.2008.00083.
7. Kim MN, Shin JH, Sung H, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48(6):e57-e61. doi: 10.1086/597108.
8. Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139-3142. doi:10.1128/JCM.00319-11.
9. Cortegiani A, Misseri G, Fasciana T, et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6(69). doi:10.1186/s40560-018-0342-4.
10. Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2017;31(1):e00029-17. doi:10.1128/CMR.00029-17.
11. Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents Confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134-140. doi:10.1093/cid/ciw691.
12. Ruiz-Gaitan A, Moret AM, Tasias-Pitarch M, et al. An outbreak due to Candida auris with prolonged colonization and candidaemia in a tertiary care European hospital. Mycoses. 2018;61:498-505. doi:10.1111/myc.12781.
13. Kwon YJ, Shin JH, Byun SA, et al. Candida auris clinical isolates from south Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2019;57(4):e01624-18. doi:10.1128/JCM.01624-18.
14. Kean R, Ramage G. Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris. mSphere. 2019;4(4):e00458-19. doi:10.1128/mSphere.00458-19.
15. Centers for Disease Control and Prevention [Internet], Antibiotic Resistance Threat Report [cited 2019 Novemder 13]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
16. Munoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. doi:10.1038/s41467-018-07779-6.
17. Ben-Ami R, Berman J, Novikov A, et al. Multidrug-Resistant, Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195-203. doi:10.3201/eid2302.161486.
18. Rudramurthy SM, Chakrabarti A, Paul RA, et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72(6):1794-1801. doi:10.1093/jac/dkx034.
19. Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155-165. doi:10.2147/IDR.S116229.
20. Osei Sekyere J. Candida auris: a systematic review and metaanalysis of current updates on an emerging multidrug-resistant pathogen [published correction appears in Microbiologyopen. 2019;8(8):e00901]. Microbiologyopen. 2018;7(4):e00578. doi:10.1002/mbo3.578.
21. Vasilyeva N, Kruglov A, Pchelin I, et al. The first Russian case of candidaemia due to Candida auris. 28th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain 21-24 April 2018.
22. Kohlenberg A, Struelens MJ, Monnet DL, et al.; The Candida Auris Survey Collaborative Group. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. 2018;23(13):18-00136. doi:10.2807/1560-7917.ES.2018.23.13.18-00136.
23. Centers for Disease Control and Prevention [Internet], CDC report of Tracking Candida auris [cited 2019 December 11]. Available from: https://www.cdc.gov/fungal/diseases/candidiasis/tracking-c-auris.html.
24. Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: ‘new kid on the block' in hospital-associated infections. J Hosp Infect. 2016;94(3):209-212. doi:10.1016/j.jhin.2016.08.004.
25. De Cassia Orlandi Sardi J, Silva DR, Soares Mendes-Giannini MJ, et al. Candida auris: epidemiology, risk factors, virulence, resistance, and therapeutic options. Microb Pathog. 2018;125:116-121. doi:10.1016/j.micpath.2018.09.014.
26. Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5(35). doi:10.1186/s13756-016-0132-5.
27. Welsh RM, Bentz ML, Shams A, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55(10):2996-3005. doi:10.1128/JCM.00921-17.
28. Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus — United States, May 2013 — August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(44): 1234-1237. doi:10.15585/mmwr.mm6544e1.
29. Sarma S, Kumar N, Sharma S, et al. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31(1):90-91. doi:10.4103/0255-0857.108746.
30. Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere. 2016;1(4):e00189-16. doi:10.1128/mSphere.00189-16.
31. Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries. 2015;9: 435-437. doi:10.3855/jidc.4582.
32. Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of anti-fungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5):e02396-16. doi:10.1128/AAC.02396-16.
33. Sherry L, Ramage G, Kean R, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis. 2017;23(2):328-331. doi:10.3201/eid2302.161320.
34. Schwartz IS, Hammond GW. First reported case of multidrug-resistant Candida auris in Canada. Can Commun Dis Rep. 2017;43(7/8):150-153. doi:10.14745/ccdr.v43i78a02.
35. Centers for Disease Control and Prevention [Internet], Identification of Candida auris [cited 2019 October 16]. Available from: https://www.cdc.gov/fungal/candida-auris/recommendations.html.
36. Mizusawa M, Miller H, Green R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55(2):638-640. doi:10.1128/JCM.02202-16.
37. Snayd M, Dias F, Ryan RW, et al. Misidentification of Candida auris by RapID yeast plus, a commercial, biochemical enzyme-based manual rapid identification system. J Clin Microbiol. 2018; 56(5):e00080-18. doi:10.1128/JCM.00080-18.
38. Kumar A, Sachu A, Mohan K, et al. Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal's medium. Revista Iberoamericana de Micologia. 2017;34(2):109-111. doi:10.1016/j.riam.2016.11.004.
39. Centers for Disease Control and Prevention [Internet], Algorithm to identify Candida auris based on phenotypic laboratory method and initial species identification [cited 2019 October 11]. Available from: https://www.cdc.gov/fungal/candida-auris/pdf/Testing-algorithm_by-Method_508.pdf.
40. Kordalewska M, Zhao Y, Lockhart SR, et al. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J Clin Microbiol. 2017;55(8):2445-2452. doi:10.1128/JCM.00630-17.
41. Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-2017) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891-899. doi:10.1093/jac/dkx480.
42. Rybak JM, Doorley LA, Nishimoto AT, et al. Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of Candida auris. Antimicrob Agents Chemother. 2019;63(4):e00057-19. doi:10.1128/AAC.00057-19.
43. Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2014;5(4):a019752. doi:10.1101/cshperspect.a019752.
44. Escandon P Chow NA, Caceres DH, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis. 2019;68(1):15-21. doi:10.1093/cid/ciy411.
45. Kordalewska M, Lee A, Park S, et al. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother. 2018;62(6):e00238-18. doi:10.1128/AAC.00238-18.
46. Fakhim H, Chowdhary A, Prakash A, et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob Agents Chemother. 2017;61(11):e01056-17. doi:10.1128/AAC.01056-17.
47. Basso V, Garcia A, Tran DQ, et al. Fungicidal potency and mechanisms of 0-defensins against multidrug-resistant Candida species. Antimicrob Agents Chemother. 2018;62(6):e00111-18. doi:10.1128/AAC.00111-18.
48. Berkow EL, Angulo D, Lockhart SR. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7):e00435-17. doi:10.1128/AAC.00435-17.
49. Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018;90(3):196-197. doi:10.1016/j.diagmicrobio.2017.10.021.
50. Zhao M, Lepak AJ, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother. 2018;62(4):e02542-17. doi:10.1128/AAC.02542-17.
51. Centers for Disease Control and Prevention [Internet], Infection Prevention and Control for Candida auris [cited 2018 December 21]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html.
52. Cadnum JL, Shaikh AA, Piedrahita CT, et al. Relative resistance of the emerging fungal pathogen Candida auris and other Candida species to killing by ultraviolet light. Infect Control Hosp Epidemiol. 2018;39(1):94-96. doi:10.1017/ice.2017.239.
53. Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilised for skin decolonisation and en-vironmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;60(11):758-763. doi:10.1111/myc.12699.
Рецензия
Для цитирования:
Иванов А.А., Куличенко Т.В. Candida auris: проблемы диагностики и лечения. Вопросы современной педиатрии. 2020;19(1):20-25. https://doi.org/10.15690/vsp.v19i1.2081
For citation:
Ivanov A.A., Kulichenko T.V. Candida auris: Problems in Diagnostics and Management. Current Pediatrics. 2020;19(1):20-25. (In Russ.) https://doi.org/10.15690/vsp.v19i1.2081
Просмотров: 4586
Послать статью по эл. почте 
